Additionally, the use of poly(I:C) agonists may be best for types of cancer that have a high incidence of TLR3-enhancing p53 mutants like the R337H mutation, that has been identified in subjects with Li-Fraumeni-like syndrome with pediatric adrenal cortical carcinoma, which has a significantly increased frequency in Brazil [47]. This evidence concerns the gene TLR3 and adrenal cortex carcinoma.